Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as ��Jt5ttf�%PJ)

(Stock Code: 01099) ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD FOR THE THREE MONTHS ENDED 31 MARCH 2015

Reference is made to the overseas regulatory announcement dated 24 April 2015 (the "Announcement") and issued by Sinopharm Group Co. Ltd. (the "Company") in relation to the first quarterly report for the three months ended 31 March 2015 of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code: 000028 for A shares;
200028 for B shares).
The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Sinopharm Accord for the three months ended 31 March 2015 as set out in the Announcement.
1

PRINCIPAL FINANCIAL DATA OF SINOPHARM ACCORD

Unit: Yuan
Currency: RMB

Current period Same period of last year Changes of this period over same period of last year

Operating income 6,261,714,700.23 5,533,524,159.08 13.16%
Net profit attributable to shareholders of the
listed company 197,026,237.82 167,818,387.39 17.40%
Net profit attributable to shareholders of the
listed company after deducting
non-recurring gains and losses 192,315,542.07 165,006,263.57 16.55%
Net cash flow arising from

operating activities

182,179,606.70

-425,683,165.96

142.80%

Basic earnings per share

(RMB/Share)

0.543

0.582

-6.70%

Diluted earnings per share
(RMB/Share) 0.543 0.582 -6.70%
Weighted average ROE 4.05% 7.21% -3.16%

At the end of the reporting period At the end of last year Changes of this period-end over same period-end of last year

Total assets 13,399,261,901.35 12,828,941,540.90 4.45%
Net assets attributable to shareholder of listed
company 4,961,634,059.91 4,764,607,822.09 4.14%
2
This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
By order of the Board

Sinopharm Group Co. Ltd. Wei Yulin

Chairman

Shanghai, the PRC
24 April 2015

As at the date of this announcement, the executive directors of the Company are Mr. Wei Yulin and Mr. Li Zhiming; the non-executive directors of the Company are Mr. Chen Qi Yu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Li Yuhua, Mr. Zhou Bin, Mr. Deng Jindong, Mr. Li Dongjiu and Mr. Liu Hailiang; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Lyu Changjiang, Mr. Tan Wee Seng and Mr. Liu Zhengdong.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its

Chinese name and the English name "Sinopharm Group Co. Ltd."

3

distributed by